Entero Therapeutics, Inc. (ENTO) 10-Year Financial Performance & Capital Metrics

ENTO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Show more

Revenue $0
EBITDA $33K +100.2%
Net Income -$18M -14.3%
EPS (Diluted) -5.26 +88.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.82% +88.2%
ROIC -0.04% +100.0%
Debt/Equity 0.00 -98.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓Trading at only 0.2x book value

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-57.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.32%

ROCE

10Y Avg-247.25%

5Y Avg-502.37%

3Y Avg-502.37%

Latest-0.05%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	734.5K	754K	798.45K	976.98K	571.14K	537.4K	106.21K	29.27K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-734.5K	-754K	-798.45K	-976.98K	-571.14K	-537.4K	-106.21K	-29.27K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-0.03%	-0.06%	-0.22%	0.42%	0.06%	0.8%	0.72%	1%
Operating Expenses+	4.34K	8.65K	10.22K	13.43K	14.74K	26.43M	56.7M	12.68M	15.77M	15.62K
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.33K	4.13K	7.69K	7.45K	6.06K	7.29M	18.38M	11.99M	10.74M	14.72K
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	1.4K	2.5K	2.4K	5.77K	8.68K	19.14M	38.32M	691.26K	5.03M	904
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	211.43K	529.1K	0	0	0
Operating Income+	-4.73K	-6.63K	-10.08K	-13.22K	-14.74K	-26.43M	-59.06M	-12.68M	-15.77M	-15.62K
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.62%	-0.4%	-0.52%	-0.31%	-0.12%	-1791.81%	-1.23%	0.79%	-0.24%	1%
EBITDA+	-4K	-5.89K	-9.33K	-12.42K	-14.11K	-25.87M	-58.51M	-12.65M	-15.74M	33.33K
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.61%	-0.47%	-0.58%	-0.33%	-0.14%	-1832.44%	-1.26%	0.78%	-0.24%	1%
D&A (Non-Cash Add-back)	734	734	754	798	635	565.35K	542.25K	29.27K	29.27K	48.95K
EBIT	-4.34M	-8.65M	-10.22M	-13.43M	-14.74M	-26.83M	-58.53M	-14.61M	-15.77M	-15.62K
Net Interest Income+	0	0	0	0	0	-5.84M	-10.06K	-7.46K	-19.93K	1
Interest Income	1.59K	5.94K	875	102	0	484	1.17K	8.41K	2.53K	1
Interest Expense	0	0	0	0	0	5.84M	11.23K	15.88K	22.46K	0
Other Income/Expense	-1.2M	-7.97M	-1.02M	-311.85K	-433.94K	-6.24M	-1.83M	-1.95M	-24.16K	2
Pretax Income+	-5.93K	-14.59K	-11.1K	-13.53K	-15.18K	-32.67M	-58.54M	-14.63M	-15.79M	-15.62K
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1000%	1000%	1000%	1000%	1000%	1%	1%	1%	1%	1156.24%
Net Income+	-5.93M	-14.59M	-11.1M	-13.53M	-15.18M	-32.67M	-58.54M	-14.63M	-15.79M	-18.06M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.51%	-1.46%	0.24%	-0.22%	-0.12%	-1.15%	-0.79%	0.75%	-0.08%	-0.14%
Net Income (Continuing)	-5.93M	-14.59M	-11.1M	-13.53M	-15.18M	-32.67M	-58.54M	-14.63M	-15.79M	-15.62K
Discontinued Operations	0	0	0	0	0	0	0	0	0	-2.44M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-25480.07	-94215.17	-43847.52	-36815.89	-28425.72	-48255.29	-27544.98	-407.37	-46.96	-5.26
EPS Growth %	-1.51%	-2.7%	0.53%	0.16%	0.23%	-0.7%	0.43%	0.99%	0.88%	0.89%
EPS (Basic)	-25480.07	-94215.17	-43847.52	-36815.89	-28425.72	-48255.29	-27544.98	-407.37	-46.96	-3.88
Diluted Shares Outstanding	233	155	253	368	534	677	2.13K	35.91K	336.34K	3.43M
Basic Shares Outstanding	233	155	253	368	534	677	2.13K	35.91K	336.34K	4.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.07K	2.96M	1.95M	4.8M	3.41K	7.87M	9.42M	3.41M	4.96M	83.48M
Cash & Short-Term Investments	639	1.77M	573.47K	1.11M	176	6.06M	8.25M	1.36M	3.71M	163.48K
Cash Only	582	1.77M	573.47K	1.11M	176	6.06M	8.25M	1.36M	3.71M	163.48K
Short-Term Investments	57	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.07M	961.04K	298.47K	3.17M	2.64M	551.49K	0	93.01K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	-2.64M	1.25M	0	1.95M	0	0
Days Inventory Outstanding	-	-	-	-	-	801.61	-	6.72K	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	83.17M
Total Non-Current Assets+	4.62K	3.79M	4.6M	2.67M	5.5K	5.05M	2.37M	2.03M	1.93M	1.93M
Property, Plant & Equipment	176	151.62K	133.99K	128.85K	160	92.57K	409.31K	303.1K	210K	126.75K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.83K	1.77M	2.02M	1.92M	1.89K	2.05M	1.91M	1.68M	1.68M	1.68M
Intangible Assets	2.58K	1.84K	1.35K	570	3.41M	2.88M	0	0	0	0
Long-Term Investments	0	0	1.07M	0	0	0	0	21.51K	21.52K	21.52K
Other Non-Current Assets	26	3.63M	30.92K	2.54M	41	27.92K	44.01K	39.66K	11.25K	98.25K
Total Assets+	6.69K	6.75M	6.55M	7.47M	8.9K	12.92M	11.79M	5.44M	6.88M	85.41M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.02%	1009.19%	-0.03%	0.14%	-1%	1450.65%	-0.09%	-0.54%	0.27%	11.41%
Total Current Liabilities+	8.82K	2.34M	2.48M	3M	4.29K	15.55M	12.3M	2.48M	3.13M	27.55M
Accounts Payable	409.41K	1.07M	1.57M	2.2M	2.22M	1.56M	2.71M	720.04K	554.28K	2.96M
Days Payables Outstanding	-	532.89	761.54	1.01K	828.25	996.04	1.84K	2.47K	6.91K	-
Short-Term Debt	6.58M	155.19K	416.55K	255.03K	1.52M	552.4K	641.24K	603.49K	612.78K	0
Deferred Revenue (Current)	0	-1.07K	0	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	993.61K	80.94K	0	0	0	0	14.82K	12.14K	1.4M	22.94M
Current Ratio	0.23x	1.27x	0.79x	1.60x	0.80x	0.51x	0.77x	1.37x	1.58x	3.03x
Quick Ratio	0.23x	1.27x	0.79x	1.60x	616.18x	0.43x	0.77x	0.59x	1.58x	3.03x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	1.2M	1.34M	0	0	19.12K	7.31M	214.06K	146.95K	59.02K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	19.12K	311.14K	214.06K	146.95K	59.02K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.5M	1.2M	1.34M	0	0	0	7M	0	0	0
Total Liabilities	8.82K	3.54M	3.82M	3M	4.29K	15.56M	19.61M	2.7M	3.28M	27.61M
Total Debt+	6.58K	155.19K	416.55K	255.03K	1.52K	628.95K	1.03M	883.71K	826.84K	140.53K
Net Debt	6K	-1.62M	-156.93K	-859.31K	1.35K	-5.43M	-7.22M	-479.2K	-2.88M	-22.94K
Debt / Equity	-	0.05x	0.15x	0.06x	0.33x	-	-	0.32x	0.23x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.22x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.69x
Interest Coverage	-	-	-	-	-	-4.53x	-5256.51x	-798.42x	-702.08x	-
Total Equity+	-3.63K	3.21M	2.73M	4.47M	4.62K	-2.64M	-7.82M	2.74M	3.6M	57.8M
Equity Growth %	-2.37%	886.17%	-0.15%	0.64%	-1%	-572.92%	-1.96%	1.35%	0.31%	15.04%
Book Value per Share	-15.60	20745.65	10794.20	12170.40	8.65	-3900.27	-3680.43	76.36	10.71	16.83
Total Shareholders' Equity	-3.63K	3.21M	2.73M	4.47M	4.62K	-2.64M	-7.82M	2.74M	3.6M	57.8M
Common Stock	0	963	1.21K	1.77K	3	312	7	5	156	475
Retained Earnings	-8.29K	-22.89M	-33.98M	-47.52M	-62.7K	-95.37M	-153.9M	-168.53M	-184.33M	-202.39M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.35K	-1.46M	-955.72K	-1.15M	-1.27M	-1.11M	-1.22M	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.17K	-4.53M	-7.18M	-10.87M	-14.03K	-11.22M	-32.29M	-22.34M	-12.38M	-9.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-3.12%	-1086.43%	-0.58%	-0.51%	1%	-798.62%	-1.88%	0.31%	0.45%	0.26%
Net Income	-5.93K	-14.59M	-11.1M	-13.53M	-15.18K	-32.67M	-58.54M	-14.63M	-15.79M	-18.06M
Depreciation & Amortization	734	734.5K	754K	798.45K	635	565.35K	542.25K	29.27K	29.27K	48.95K
Stock-Based Compensation	0	604	2.02K	2.84K	1.39K	549.42K	1.37M	769.12K	1.04M	631.55K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.68K	9.95M	5.16M	6.62M	397	5.4M	3.46M	277.43K	157.02K	5.63M
Working Capital Changes	-653	704.87K	-268.2K	-1.71M	-1.28K	14.15M	17.1M	-10.5M	2.19M	2.53M
Change in Receivables	-638	132.04K	3.44K	-2.19M	-750	2.08K	551	-93	93.01K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-233.78K	741.62K	-420.79K	-750.03K	1.42M	-1.99M	-165.76K	1.64M
Cash from Investing+	-24	-12.36K	-32.17K	-305.47K	-24	87.35K	-10.32M	0	-500K	88.17K
Capital Expenditures	-24	-12.36K	-32.17K	-305.47K	-24.1K	-4.17K	-10.32M	0	-500K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	92	-10.25K	0	0	0
Cash from Financing+	4.68K	5.75M	6.01M	11.71M	13.14K	17.05M	44.76M	15.74M	15.23M	5.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-340.52K	-1.42M	0	0	61.59K	0	4.91M	-6.87M	657	45
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.2K	-4.55M	-7.22M	-11.17M	-38.13K	-11.23M	-42.61M	-22.34M	-12.88M	-9.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-2.49%	-1083.06%	-0.59%	-0.55%	1%	-293.39%	-2.8%	0.48%	0.42%	0.28%
FCF per Share	-18.02	-29360.37	-28517.32	-30399.11	-71.42	-16580.21	-20049.05	-622.19	-38.29	-2.68
FCF Conversion (FCF/Net Income)	0.00x	0.31x	0.65x	0.80x	0.00x	0.34x	0.55x	1.53x	0.78x	0.51x
Interest Paid	0	0	0	0	0	0	0	0	0	36.16K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-909.32%	-373.32%	-375.65%	-677.8%	-	-	-533.51%	-497.87%	-58.82%
Return on Invested Capital (ROIC)	-118.85%	-0.62%	-0.36%	-0.32%	-0.61%	-	-	-	-793.58%	-0.04%
Debt / Equity	-	0.05x	0.15x	0.06x	0.33x	-	-	0.32x	0.23x	0.00x
Interest Coverage	-	-	-	-	-	-4.53x	-5256.51x	-798.42x	-702.08x	-
FCF Conversion	0.00x	0.31x	0.65x	0.80x	0.00x	0.34x	0.55x	1.53x	0.78x	0.51x

Frequently Asked Questions

Growth & Financials

Entero Therapeutics, Inc. (ENTO) grew revenue by 0.0% over the past year. Growth has been modest.

Entero Therapeutics, Inc. (ENTO) reported a net loss of $15.6M for fiscal year 2024.

Dividend & Returns

Entero Therapeutics, Inc. (ENTO) has a return on equity (ROE) of -58.8%. Negative ROE indicates the company is unprofitable.

Entero Therapeutics, Inc. (ENTO) had negative free cash flow of $1.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Entero Therapeutics, Inc. (ENTO) 10-Year Financial Performance & Capital Metrics

ENTO • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA $33K +100.2%
Net Income -$18M -14.3%
EPS (Diluted) -5.26 +88.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.82% +88.2%
ROIC -0.04% +100.0%
Debt/Equity 0.00 -98.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)
✓Trading at only 0.2x book value

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-57.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.32%

ROCE

10Y Avg-247.25%

5Y Avg-502.37%

3Y Avg-502.37%

Latest-0.05%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	734.5K	754K	798.45K	976.98K	571.14K	537.4K	106.21K	29.27K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-734.5K	-754K	-798.45K	-976.98K	-571.14K	-537.4K	-106.21K	-29.27K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-0.03%	-0.06%	-0.22%	0.42%	0.06%	0.8%	0.72%	1%
Operating Expenses+	4.34K	8.65K	10.22K	13.43K	14.74K	26.43M	56.7M	12.68M	15.77M	15.62K
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.33K	4.13K	7.69K	7.45K	6.06K	7.29M	18.38M	11.99M	10.74M	14.72K
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	1.4K	2.5K	2.4K	5.77K	8.68K	19.14M	38.32M	691.26K	5.03M	904
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	211.43K	529.1K	0	0	0
Operating Income+	-4.73K	-6.63K	-10.08K	-13.22K	-14.74K	-26.43M	-59.06M	-12.68M	-15.77M	-15.62K
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.62%	-0.4%	-0.52%	-0.31%	-0.12%	-1791.81%	-1.23%	0.79%	-0.24%	1%
EBITDA+	-4K	-5.89K	-9.33K	-12.42K	-14.11K	-25.87M	-58.51M	-12.65M	-15.74M	33.33K
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.61%	-0.47%	-0.58%	-0.33%	-0.14%	-1832.44%	-1.26%	0.78%	-0.24%	1%
D&A (Non-Cash Add-back)	734	734	754	798	635	565.35K	542.25K	29.27K	29.27K	48.95K
EBIT	-4.34M	-8.65M	-10.22M	-13.43M	-14.74M	-26.83M	-58.53M	-14.61M	-15.77M	-15.62K
Net Interest Income+	0	0	0	0	0	-5.84M	-10.06K	-7.46K	-19.93K	1
Interest Income	1.59K	5.94K	875	102	0	484	1.17K	8.41K	2.53K	1
Interest Expense	0	0	0	0	0	5.84M	11.23K	15.88K	22.46K	0
Other Income/Expense	-1.2M	-7.97M	-1.02M	-311.85K	-433.94K	-6.24M	-1.83M	-1.95M	-24.16K	2
Pretax Income+	-5.93K	-14.59K	-11.1K	-13.53K	-15.18K	-32.67M	-58.54M	-14.63M	-15.79M	-15.62K
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1000%	1000%	1000%	1000%	1000%	1%	1%	1%	1%	1156.24%
Net Income+	-5.93M	-14.59M	-11.1M	-13.53M	-15.18M	-32.67M	-58.54M	-14.63M	-15.79M	-18.06M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.51%	-1.46%	0.24%	-0.22%	-0.12%	-1.15%	-0.79%	0.75%	-0.08%	-0.14%
Net Income (Continuing)	-5.93M	-14.59M	-11.1M	-13.53M	-15.18M	-32.67M	-58.54M	-14.63M	-15.79M	-15.62K
Discontinued Operations	0	0	0	0	0	0	0	0	0	-2.44M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-25480.07	-94215.17	-43847.52	-36815.89	-28425.72	-48255.29	-27544.98	-407.37	-46.96	-5.26
EPS Growth %	-1.51%	-2.7%	0.53%	0.16%	0.23%	-0.7%	0.43%	0.99%	0.88%	0.89%
EPS (Basic)	-25480.07	-94215.17	-43847.52	-36815.89	-28425.72	-48255.29	-27544.98	-407.37	-46.96	-3.88
Diluted Shares Outstanding	233	155	253	368	534	677	2.13K	35.91K	336.34K	3.43M
Basic Shares Outstanding	233	155	253	368	534	677	2.13K	35.91K	336.34K	4.65M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.07K	2.96M	1.95M	4.8M	3.41K	7.87M	9.42M	3.41M	4.96M	83.48M
Cash & Short-Term Investments	639	1.77M	573.47K	1.11M	176	6.06M	8.25M	1.36M	3.71M	163.48K
Cash Only	582	1.77M	573.47K	1.11M	176	6.06M	8.25M	1.36M	3.71M	163.48K
Short-Term Investments	57	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.07M	961.04K	298.47K	3.17M	2.64M	551.49K	0	93.01K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	-2.64M	1.25M	0	1.95M	0	0
Days Inventory Outstanding	-	-	-	-	-	801.61	-	6.72K	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	83.17M
Total Non-Current Assets+	4.62K	3.79M	4.6M	2.67M	5.5K	5.05M	2.37M	2.03M	1.93M	1.93M
Property, Plant & Equipment	176	151.62K	133.99K	128.85K	160	92.57K	409.31K	303.1K	210K	126.75K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	1.83K	1.77M	2.02M	1.92M	1.89K	2.05M	1.91M	1.68M	1.68M	1.68M
Intangible Assets	2.58K	1.84K	1.35K	570	3.41M	2.88M	0	0	0	0
Long-Term Investments	0	0	1.07M	0	0	0	0	21.51K	21.52K	21.52K
Other Non-Current Assets	26	3.63M	30.92K	2.54M	41	27.92K	44.01K	39.66K	11.25K	98.25K
Total Assets+	6.69K	6.75M	6.55M	7.47M	8.9K	12.92M	11.79M	5.44M	6.88M	85.41M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.02%	1009.19%	-0.03%	0.14%	-1%	1450.65%	-0.09%	-0.54%	0.27%	11.41%
Total Current Liabilities+	8.82K	2.34M	2.48M	3M	4.29K	15.55M	12.3M	2.48M	3.13M	27.55M
Accounts Payable	409.41K	1.07M	1.57M	2.2M	2.22M	1.56M	2.71M	720.04K	554.28K	2.96M
Days Payables Outstanding	-	532.89	761.54	1.01K	828.25	996.04	1.84K	2.47K	6.91K	-
Short-Term Debt	6.58M	155.19K	416.55K	255.03K	1.52M	552.4K	641.24K	603.49K	612.78K	0
Deferred Revenue (Current)	0	-1.07K	0	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	993.61K	80.94K	0	0	0	0	14.82K	12.14K	1.4M	22.94M
Current Ratio	0.23x	1.27x	0.79x	1.60x	0.80x	0.51x	0.77x	1.37x	1.58x	3.03x
Quick Ratio	0.23x	1.27x	0.79x	1.60x	616.18x	0.43x	0.77x	0.59x	1.58x	3.03x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	1.2M	1.34M	0	0	19.12K	7.31M	214.06K	146.95K	59.02K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	19.12K	311.14K	214.06K	146.95K	59.02K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.5M	1.2M	1.34M	0	0	0	7M	0	0	0
Total Liabilities	8.82K	3.54M	3.82M	3M	4.29K	15.56M	19.61M	2.7M	3.28M	27.61M
Total Debt+	6.58K	155.19K	416.55K	255.03K	1.52K	628.95K	1.03M	883.71K	826.84K	140.53K
Net Debt	6K	-1.62M	-156.93K	-859.31K	1.35K	-5.43M	-7.22M	-479.2K	-2.88M	-22.94K
Debt / Equity	-	0.05x	0.15x	0.06x	0.33x	-	-	0.32x	0.23x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.22x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.69x
Interest Coverage	-	-	-	-	-	-4.53x	-5256.51x	-798.42x	-702.08x	-
Total Equity+	-3.63K	3.21M	2.73M	4.47M	4.62K	-2.64M	-7.82M	2.74M	3.6M	57.8M
Equity Growth %	-2.37%	886.17%	-0.15%	0.64%	-1%	-572.92%	-1.96%	1.35%	0.31%	15.04%
Book Value per Share	-15.60	20745.65	10794.20	12170.40	8.65	-3900.27	-3680.43	76.36	10.71	16.83
Total Shareholders' Equity	-3.63K	3.21M	2.73M	4.47M	4.62K	-2.64M	-7.82M	2.74M	3.6M	57.8M
Common Stock	0	963	1.21K	1.77K	3	312	7	5	156	475
Retained Earnings	-8.29K	-22.89M	-33.98M	-47.52M	-62.7K	-95.37M	-153.9M	-168.53M	-184.33M	-202.39M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.35K	-1.46M	-955.72K	-1.15M	-1.27M	-1.11M	-1.22M	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.17K	-4.53M	-7.18M	-10.87M	-14.03K	-11.22M	-32.29M	-22.34M	-12.38M	-9.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-3.12%	-1086.43%	-0.58%	-0.51%	1%	-798.62%	-1.88%	0.31%	0.45%	0.26%
Net Income	-5.93K	-14.59M	-11.1M	-13.53M	-15.18K	-32.67M	-58.54M	-14.63M	-15.79M	-18.06M
Depreciation & Amortization	734	734.5K	754K	798.45K	635	565.35K	542.25K	29.27K	29.27K	48.95K
Stock-Based Compensation	0	604	2.02K	2.84K	1.39K	549.42K	1.37M	769.12K	1.04M	631.55K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.68K	9.95M	5.16M	6.62M	397	5.4M	3.46M	277.43K	157.02K	5.63M
Working Capital Changes	-653	704.87K	-268.2K	-1.71M	-1.28K	14.15M	17.1M	-10.5M	2.19M	2.53M
Change in Receivables	-638	132.04K	3.44K	-2.19M	-750	2.08K	551	-93	93.01K	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	-233.78K	741.62K	-420.79K	-750.03K	1.42M	-1.99M	-165.76K	1.64M
Cash from Investing+	-24	-12.36K	-32.17K	-305.47K	-24	87.35K	-10.32M	0	-500K	88.17K
Capital Expenditures	-24	-12.36K	-32.17K	-305.47K	-24.1K	-4.17K	-10.32M	0	-500K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	92	-10.25K	0	0	0
Cash from Financing+	4.68K	5.75M	6.01M	11.71M	13.14K	17.05M	44.76M	15.74M	15.23M	5.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-340.52K	-1.42M	0	0	61.59K	0	4.91M	-6.87M	657	45
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.2K	-4.55M	-7.22M	-11.17M	-38.13K	-11.23M	-42.61M	-22.34M	-12.88M	-9.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-2.49%	-1083.06%	-0.59%	-0.55%	1%	-293.39%	-2.8%	0.48%	0.42%	0.28%
FCF per Share	-18.02	-29360.37	-28517.32	-30399.11	-71.42	-16580.21	-20049.05	-622.19	-38.29	-2.68
FCF Conversion (FCF/Net Income)	0.00x	0.31x	0.65x	0.80x	0.00x	0.34x	0.55x	1.53x	0.78x	0.51x
Interest Paid	0	0	0	0	0	0	0	0	0	36.16K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-909.32%	-373.32%	-375.65%	-677.8%	-	-	-533.51%	-497.87%	-58.82%
Return on Invested Capital (ROIC)	-118.85%	-0.62%	-0.36%	-0.32%	-0.61%	-	-	-	-793.58%	-0.04%
Debt / Equity	-	0.05x	0.15x	0.06x	0.33x	-	-	0.32x	0.23x	0.00x
Interest Coverage	-	-	-	-	-	-4.53x	-5256.51x	-798.42x	-702.08x	-
FCF Conversion	0.00x	0.31x	0.65x	0.80x	0.00x	0.34x	0.55x	1.53x	0.78x	0.51x

Frequently Asked Questions

Growth & Financials

Entero Therapeutics, Inc. (ENTO) grew revenue by 0.0% over the past year. Growth has been modest.

Entero Therapeutics, Inc. (ENTO) reported a net loss of $15.6M for fiscal year 2024.

Dividend & Returns

Entero Therapeutics, Inc. (ENTO) has a return on equity (ROE) of -58.8%. Negative ROE indicates the company is unprofitable.

Entero Therapeutics, Inc. (ENTO) had negative free cash flow of $1.9M in fiscal year 2024, likely due to heavy capital investments.